SCHEMBL3403474

SCHEMBL3403474

COC(=O)c1nn(Cc2ccc(C(=O)N3CCOCC3)cc2)c2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 6/20 0.50
F2 P00734 1/20 0.50
PLAU P00749 1/20 0.50
ELANE P08246 1/20 0.50
IDO1 P14902 1/20 0.48
TDO2 P48775 1/20 0.48
PTGS1 P23219 1/20 0.48
PTGS2 P35354 1/20 0.48
MAPK10 P53779 1/20 0.48
PIK3CD O00329 2/20 0.46
PIK3R2 O00459 2/20 0.46
PIK3CA P42336 2/20 0.46
PIK3CB P42338 2/20 0.46
PIK3CG P48736 2/20 0.46
PIK3R5 Q8WYR1 2/20 0.46
PIK3R3 Q92569 2/20 0.46
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3428165 0.88 PTGER4 (0.54) PTGER4IDO1TDO2PTGS1PTGS2
SCHEMBL3428309 0.85 PTGER4 (0.59) PTGER4PIK3CDPIK3R2PIK3CAPIK3CB
SCHEMBL3428148 0.81 FLT3 (0.55) PTGER4ELANEIDO1TDO2HPGD
SCHEMBL3428968 0.81 FLT3 (0.52) PTGER4ELANEIDO1TDO2HPGD
SCHEMBL3428482 0.81 PTGER4 (0.61) PTGER4MAPK10SMN1; SMN2
SCHEMBL1897336 0.80 PTGER4 (0.59) PTGER4F2PLAUELANESMN1; SMN2
SCHEMBL24273650 0.79 PTGER4 (0.61) PTGER4F2PLAUELANESMN1; SMN2
SCHEMBL29459644 0.79 PTGER4 (0.61) PTGER4F2PLAUELANESMN1; SMN2
SCHEMBL3431403 0.79 RAB9A (0.56) ELANESMN1; SMN2
SCHEMBL3762123 0.79 PTGER4 (0.50) PTGER4PIK3CDPIK3R2PIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 PTGER4 3500/4885F2 3808/4885PLAU 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.